Northern Trust’s Adverum Biotechnologies ADVM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-28,058
Closed -$127K 4451
2025
Q3
$127K Sell
28,058
-6,333
-18% -$18.7K ﹤0.01% 4081
2025
Q2
$73.9K Sell
34,391
-115,981
-77% -$324K ﹤0.01% 4171
2025
Q1
$657K Sell
150,372
-2,205
-1% -$9.94K ﹤0.01% 3462
2024
Q4
$713K Sell
152,577
-2,420
-2% -$16.3K ﹤0.01% 3528
2024
Q3
$1.09M Buy
154,997
+107,834
+229% +$783K ﹤0.01% 3330
2024
Q2
$324K Buy
47,163
+10,423
+28% +$96.9K ﹤0.01% 3667
2024
Q1
$520K Buy
36,740
+18,705
+104% +$284K ﹤0.01% 3552
2023
Q4
$136K Hold
18,035
﹤0.01% 4033
2023
Q3
$271K Sell
18,035
-65
-0.4% -$1.17K ﹤0.01% 3705
2023
Q2
$288K Sell
18,100
-55
-0.3% -$578 ﹤0.01% 3685
2023
Q1
$130K Sell
18,155
-63
-0.3% -$446 ﹤0.01% 4011
2022
Q4
$106K Buy
18,218
+1,589
+10% +$12K ﹤0.01% 4073
2022
Q3
$158K Buy
16,629
+337
+2% +$4.43K ﹤0.01% 3970
2022
Q2
$195K Sell
16,292
-59,566
-79% -$624K ﹤0.01% 3937
2022
Q1
$994K Sell
75,858
-3,182
-4% -$46.6K ﹤0.01% 3418
2021
Q4
$1.39M Sell
79,040
-8,674
-10% -$174K ﹤0.01% 3405
2021
Q3
$1.9M Sell
87,714
-4,476
-5% -$114K ﹤0.01% 3317
2021
Q2
$3.23M Sell
92,190
-5,947
-6% -$320K ﹤0.01% 3108
2021
Q1
$9.68M Sell
98,137
-7,016
-7% -$842K ﹤0.01% 2312
2020
Q4
$11.4M Sell
105,153
-954
-0.9% -$118K ﹤0.01% 2168
2020
Q3
$10.9M Buy
106,107
+11,211
+12% +$1.68M ﹤0.01% 2065
2020
Q2
$19.8M Buy
94,896
+14,776
+18% +$2.62M ﹤0.01% 1631
2020
Q1
$7.83M Buy
80,120
+13,265
+20% +$1.55M ﹤0.01% 2033
2019
Q4
$7.7M Buy
66,855
+3,339
+5% +$294K ﹤0.01% 2340
2019
Q3
$3.46M Buy
63,516
+3,236
+5% +$365K ﹤0.01% 2767
2019
Q2
$7.17M Sell
60,280
-151
-0.2% -$12.5K ﹤0.01% 2353
2019
Q1
$3.17M Buy
60,431
+4
+0% +$162 ﹤0.01% 2815
2018
Q4
$1.9M Sell
60,427
-928
-2% -$37.7K ﹤0.01% 3083
2018
Q3
$3.71M Buy
61,355
+3,431
+6% +$193K ﹤0.01% 2870
2018
Q2
$3.07M Buy
57,924
+47,940
+480% +$2.88M ﹤0.01% 2970
2018
Q1
$579K Buy
9,984
+1,949
+24% +$121K ﹤0.01% 3524
2017
Q4
$281K Buy
8,035
+2,685
+50% +$88.4K ﹤0.01% 3699
2017
Q3
$195K Buy
5,350
+2,127
+66% +$59K ﹤0.01% 3803
2017
Q2
$80K Sell
3,223
-18,802
-85% -$514K ﹤0.01% 4013
2017
Q1
$595K Sell
22,025
-245
-1% -$6.97K ﹤0.01% 3488
2016
Q4
$646K Buy
22,270
+144
+0.7% +$4.71K ﹤0.01% 3470
2016
Q3
$910K Sell
22,126
-14,949
-40% -$567K ﹤0.01% 3371
2016
Q2
$1.17M Buy
37,075
+15,591
+73% +$704K ﹤0.01% 3298
2016
Q1
$1.11M Sell
21,484
-234
-1% -$13.1K ﹤0.01% 3218
2015
Q4
$2.07M Buy
21,718
+767
+4% +$67.4K ﹤0.01% 3045
2015
Q3
$1.73M Buy
20,951
+10,748
+105% +$1.37M ﹤0.01% 3118
2015
Q2
$1.66M Buy
10,203
+1,957
+24% +$660K ﹤0.01% 3147
2015
Q1
$3.34M Buy
8,246
+1,125
+16% +$476K ﹤0.01% 2777
2014
Q4
$3.85M Buy
7,121
+5,673
+392% +$2.19M ﹤0.01% 2665
2014
Q3
$495K Buy
+1,448
New +$431K ﹤0.01% 3573

Northern Trust's ADVM Position: Q4 2025 in Review

Northern Trust sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 28,058 shares — an estimated $127K sold.

Northern Trust first reported a position in ADVM in Q3 2014 and held it in 45 quarters. The position peaked at $19.8M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • Northern Trust reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Northern Trust sold 28,058 Adverum Biotechnologies shares in Q4 2025, an estimated $127K.
  • Northern Trust first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 45 quarters.
  • Northern Trust's Adverum Biotechnologies position peaked at $19.8M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Northern Trust's 13F filing for Q4 2025, filed 17 Feb 2026.